Cart
sales@molnova.com
Ruplizumab
CAS No. 220651-94-5
Ruplizumab( —— )
Catalog No. M36733 CAS No. 220651-94-5
Ruplizumab (BG 9588), a humanized monoclonal IgG1κ antibody targeting CD40L (TNF Receptor), holds promise for research in systemic lupus erythematosus disease .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 369 | Get Quote |
|
| 5MG | 601 | Get Quote |
|
| 10MG | 823 | Get Quote |
|
| 25MG | 1178 | Get Quote |
|
| 50MG | 1592 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameRuplizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionRuplizumab (BG 9588), a humanized monoclonal IgG1κ antibody targeting CD40L (TNF Receptor), holds promise for research in systemic lupus erythematosus disease .
-
DescriptionRuplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number220651-94-5
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Chris Chamberlain, et al. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles. Ann Rheum Dis. 2017 Nov;76(11):1837-1844.?
molnova catalog
related products
-
L-2-Phosphoglyceric ...
2-Phosphoglyceric acid (2PGA) is a glyceric acid which serves as the substrate in the ninth step of glycolysis. It is catalyzed by enolase into phosphoenolpyruvate (PEP) the penultimate step in the conversion of glucose to pyruvate.
-
PKUMDL-WQ-2101
PKUMDL-WQ-2101 is a selective allosteric inhibitor of phosphoglycerate dehydrogenase (PHGDH) with anti-tumor activity, it binds to site I.
-
I-152
I-152, a conjugate of N-acetyl-cysteine (NAC) and cysteamine (MEA), activates NRF2 and ATF4 signaling pathways and exhibits anti-proliferative properties .
